Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Aging (NIA)
• Treatments: Guanfacine

Criteria

Inclusion Criteria:

Subjects enrolled will be nondemented, male and female individuals who meet the following inclusion criteria:

• 75 years of age or older

• Fluent in English

• Stable medical condition for at least 4 weeks prior to Screening visit

• Stable dose of non-excluded medications for at least 4 weeks prior to Screening visit

Exclusion Criteria:

• Dementia

• Mild Cognitive Impairment (Amnestic MCI)

• Clinically significant neurologic disease

• Clinically significant or unstable medical conditions that would interfere with participation in the trial

• Known hypersensitivity to guanfacine

• History of alcohol or substance abuse or dependence within the past 5 years

• Active major psychiatric disorders, including major depression

• History of mental retardation

• Significant abnormalities on clinical laboratories, ECG, or physical examination

• Impairment of visual or auditory acuity sufficient to interfere with completion of study procedures

• Education level < 6 years